Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893856990> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2893856990 abstract "Immunotherapies have revolutionized cancer treatment. Unlike chemotherapies, immune agents often take longer time to show benefit, and the complex and unique mechanism of action of these agents renders the use of multiple endpoints more appropriate in some trials. These new features of immunotherapy make conventional phase II trial designs, which assume a single binary endpoint that is quickly ascertainable, inefficient and dysfunctional. We propose a flexible and efficient time-to-event Bayesian optimal phase II (TOP) design. The TOP design is efficient in that it allows real-time go/no-go interim decision making in the presence of late-onset responses by using all available data, and maximizes the statistical power for detecting effective treatments. TOP is flexible in the number of interim looks and capable of handling simple and complicated endpoints under a unified framework. We conduct simulation studies to evaluate the operating characteristics of the TOP design.Compared to some existing designs, the TOP design shortens the trial duration and has higher power to detect effective treatment with well controlled type I errors. The TOP design allows for making real-time go/no-go interim decisions in the presence of late-onset responses, and is capable of handling various types of endpoints under a unified framework. It is transparent and easy to implement as its decision rules can be tabulated and included in the protocol prior to the conduct of the trial. The TOP design provides a flexible, efficient and easy-to-implement method to accelerate and improve the development of immunotherapies." @default.
- W2893856990 created "2018-10-05" @default.
- W2893856990 creator A5009234043 @default.
- W2893856990 creator A5019360674 @default.
- W2893856990 creator A5052092144 @default.
- W2893856990 date "2018-10-01" @default.
- W2893856990 modified "2023-09-25" @default.
- W2893856990 title "TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy" @default.
- W2893856990 cites W1976585131 @default.
- W2893856990 cites W2007648830 @default.
- W2893856990 cites W2019607817 @default.
- W2893856990 cites W2029409133 @default.
- W2893856990 cites W2054857153 @default.
- W2893856990 cites W2083637030 @default.
- W2893856990 cites W2103012803 @default.
- W2893856990 cites W2111137187 @default.
- W2893856990 cites W2120550913 @default.
- W2893856990 cites W2141724682 @default.
- W2893856990 cites W2263896208 @default.
- W2893856990 cites W2343362475 @default.
- W2893856990 cites W2592144107 @default.
- W2893856990 cites W2604629435 @default.
- W2893856990 cites W2609973112 @default.
- W2893856990 cites W2624426279 @default.
- W2893856990 cites W2753890414 @default.
- W2893856990 cites W2794872274 @default.
- W2893856990 cites W2809688974 @default.
- W2893856990 doi "https://doi.org/10.48550/arxiv.1810.00709" @default.
- W2893856990 hasPublicationYear "2018" @default.
- W2893856990 type Work @default.
- W2893856990 sameAs 2893856990 @default.
- W2893856990 citedByCount "0" @default.
- W2893856990 crossrefType "posted-content" @default.
- W2893856990 hasAuthorship W2893856990A5009234043 @default.
- W2893856990 hasAuthorship W2893856990A5019360674 @default.
- W2893856990 hasAuthorship W2893856990A5052092144 @default.
- W2893856990 hasBestOaLocation W28938569901 @default.
- W2893856990 hasConcept C107673813 @default.
- W2893856990 hasConcept C121332964 @default.
- W2893856990 hasConcept C142724271 @default.
- W2893856990 hasConcept C148482608 @default.
- W2893856990 hasConcept C154945302 @default.
- W2893856990 hasConcept C166957645 @default.
- W2893856990 hasConcept C204787440 @default.
- W2893856990 hasConcept C2776957806 @default.
- W2893856990 hasConcept C2779662365 @default.
- W2893856990 hasConcept C2780385302 @default.
- W2893856990 hasConcept C41008148 @default.
- W2893856990 hasConcept C535046627 @default.
- W2893856990 hasConcept C61943457 @default.
- W2893856990 hasConcept C62520636 @default.
- W2893856990 hasConcept C71924100 @default.
- W2893856990 hasConcept C95457728 @default.
- W2893856990 hasConceptScore W2893856990C107673813 @default.
- W2893856990 hasConceptScore W2893856990C121332964 @default.
- W2893856990 hasConceptScore W2893856990C142724271 @default.
- W2893856990 hasConceptScore W2893856990C148482608 @default.
- W2893856990 hasConceptScore W2893856990C154945302 @default.
- W2893856990 hasConceptScore W2893856990C166957645 @default.
- W2893856990 hasConceptScore W2893856990C204787440 @default.
- W2893856990 hasConceptScore W2893856990C2776957806 @default.
- W2893856990 hasConceptScore W2893856990C2779662365 @default.
- W2893856990 hasConceptScore W2893856990C2780385302 @default.
- W2893856990 hasConceptScore W2893856990C41008148 @default.
- W2893856990 hasConceptScore W2893856990C535046627 @default.
- W2893856990 hasConceptScore W2893856990C61943457 @default.
- W2893856990 hasConceptScore W2893856990C62520636 @default.
- W2893856990 hasConceptScore W2893856990C71924100 @default.
- W2893856990 hasConceptScore W2893856990C95457728 @default.
- W2893856990 hasLocation W28938569901 @default.
- W2893856990 hasLocation W28938569902 @default.
- W2893856990 hasOpenAccess W2893856990 @default.
- W2893856990 hasPrimaryLocation W28938569901 @default.
- W2893856990 hasRelatedWork W1974833954 @default.
- W2893856990 hasRelatedWork W2023402573 @default.
- W2893856990 hasRelatedWork W2110900782 @default.
- W2893856990 hasRelatedWork W2139024834 @default.
- W2893856990 hasRelatedWork W2224472820 @default.
- W2893856990 hasRelatedWork W2595260335 @default.
- W2893856990 hasRelatedWork W3024239282 @default.
- W2893856990 hasRelatedWork W4287775653 @default.
- W2893856990 hasRelatedWork W66630131 @default.
- W2893856990 hasRelatedWork W98011991 @default.
- W2893856990 isParatext "false" @default.
- W2893856990 isRetracted "false" @default.
- W2893856990 magId "2893856990" @default.
- W2893856990 workType "article" @default.